Biogen (BIIB)
(Delayed Data from NSDQ)
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
Biogen Alzheimer's Drug Shows Promise in Long-Term Study
by Zacks Equity Research
Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.
Company News For August 29, 2017
by Zacks Equity Research
Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ
Biogen's Humira Biosimilar Imraldi Gets Approval in EU
by Zacks Equity Research
Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.
What You See, and What You Get: The Neurology of Perception
by Kevin Cook
While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.
The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix
PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line
by Zacks Equity Research
Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Biogen (BIIB) Tops Q2 Earnings and Revenue
by Zacks Equity Research
Biogen (BIIB) reported better-than expected earnings in the second quarter of 2017 with revenue beating estimates.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.
Top Stock Reports for Boeing, AbbVie & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).
Better Days Ahead for the Pharma Sector?
by Arpita Dutt
Sales, R&D, strong results, and a higher number of FDA approvals.
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
by Zacks Equity Research
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Bear of the Day: Bioverativ (BIVV)
by Kevin Cook
Biogen spin-off just reported its first quarter and made an acquisition, but estimates were trimmed
Biogen Loses Top Executive Again, CFO Clancy to Join Alexion
by Zacks Equity Research
Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.
Biogen/Ionis Spinraza Granted Marketing Authorization in EU
by Zacks Equity Research
Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.
5 Drug Stocks in Focus on World MS Day
by Arpita Dutt
Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?
by Zacks Equity Research
On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).
Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug
by Arpita Dutt
Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.
Top Research Reports for UnitedHealth Group, Union Pacific & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (UNH), Union Pacific Corporation (UNP) and Biogen Inc (BIIB).
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
by Zacks Equity Research
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.